JP Morgan Chase’s ProShares UltraShort Health Care RXD Stock Holding History

JP Morgan Chase’s Portfolio RXD Stock Details RXD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,250	Closed	-$87.3K	–	7842
2025 Q4	$87.3K	Sell	1,250 -13,500	-92%	-$265K	﹤0.01%	5959
2025 Q3	$997K	Buy	14,750 +5,050	+52%	+$122K	﹤0.01%	4604
2025 Q2	$681K	Buy	+9,700	New	+$237K	﹤0.01%	4613
2015 Q3	–	Sell	-1,109	Closed	-$221K	–	4051
2015 Q2	$221K	Buy	+1,109	New	+$220K	﹤0.01%	3788

Other funds holding RXD

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's RXD Position: Q4 2023 in Review

JP Morgan Chase sold out of ProShares UltraShort Health Care (RXD) in Q4 2023, closing a stake of 1 share — an estimated $27 sold.

JP Morgan Chase first reported a position in RXD in Q3 2022 and held it in 5 quarters. The position peaked at $4K in Q3 2022. 3 funds tracked by Wall St. Rank hold RXD as of Q4 2023.

JP Morgan Chase reported no remaining ProShares UltraShort Health Care position as of Q4 2023 after selling out during the quarter.
JP Morgan Chase sold 1 ProShares UltraShort Health Care share in Q4 2023, an estimated $27.
JP Morgan Chase first reported a position in ProShares UltraShort Health Care in Q3 2022 and held it in 5 quarters.
JP Morgan Chase's ProShares UltraShort Health Care position peaked at $4K in Q3 2022.
3 funds tracked by Wall St. Rank held ProShares UltraShort Health Care as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.